(RTTNews) - Viatris Inc. (VTRS) announced that the U.S. Food and Drug Administration approved RYZUMVI (phentolamine ophthalmic solution 0.75%) for the treatment of presbyopia in adults.

FDA Approves Viatris' RYZUMVI For Presbyopia Treatment 

In the latest look at the underlying components of the S&P 500 ordered by largest market capitalization, Dow Inc (Symbol: DOW) has taken over the #374 spot from Viatris Inc (Symbol: VTRS), according to The Online Investor.  

	Market capitalization is an important data point

Dow Takes Over #374 Spot From Viatris 

(RTTNews) - The following biotech stocks reached a 52-week high on October 8, 2026, driven by catalysts such as reports of an upcoming acquisition or upcoming financial reports.

Biotech Stocks At 52-Week Highs - PCRX +44% On Acquisition News; MANE+14%, HAE+17%, CON, HSTM 

Key PointsPacira BioSciences is being bought out by Viatrias.

Why Pacira BioSciences Skyrocketed Today

Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the WisdomTree U.S. Value Fund (Symbol: WTV) where we have detected an approximate $263.5 million dollar inflow -- that's a 8.0% increase week over week

WisdomTree U.S. Value Fund Experiences Big Inflow

The NASDAQ 100 After Hours Indicator is up 10.14 to 30,094.64.  The total After hours volume is currently 118,663,040 shares traded.The following are the most active stocks for the after hours session: Nexgen Energy Ltd. (NXE) is -0.09 at $10.30, with 10,503,139 shares traded. As

After Hours Most Active for Aug 13, 2026 :  NXE, SOFI, VTRS, NVDA, INTC, SNAP, AAPL, BAM, MFC, LYB, SMCI, COP

Viatris Inc., together with its subsidiaries, operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East. It operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The company offers prescription brand drugs, generic drugs, complex generic drugs, and biosimilars. It also provides drugs in various therapeutic areas covering various noncommunicable and infectious diseases, including cardiovascular, CNS and anesthesia, dermatology, diabetes and metabolism, eye care, gastroenterology, immunology, oncology, and respiratory and allergy, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. In addition, the company offers medicines in the form of oral solid doses, injectables, and complex dosage forms to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. It distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies under the Lyrica, Lipitor, Celebrex, Viagra, Creon, Influvac, Wixela Inhub, EpiPen Auto-Injector, Fraxiparine, Yupelri, Norvasc, Amitiza, Effexor, Lipacreon, Zoloft, Xalabrands, Dymista, Xanax, and Breyna brands. The company has collaboration agreements with Mapi Pharma Ltd. to develop and commercialize long-acting glatiramer acetate depot products and additional products; Revance Therapeutics, Inc. to develop, manufacture, and commercialize a biosimilar to the branded biologic product, BOTOX; and Theravance Biopharma, Inc. to develop and commercialize revefenacin. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.

Viatris Inc. News